ZERIT XR
LOE ApproachingNDAORALCAPSULE, EXTENDED RELEASE
Approved
Dec 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZERIT XR is an extended-release oral capsule small molecule approved in 2002. The specific indication and mechanism of action are not provided in available data. This product is in the LOE approaching lifecycle stage, indicating mature market positioning.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100) suggests declining team investment and potential restructuring or transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings signal that ZERIT XR is a maintenance-phase product with limited active hiring. Career opportunities on this brand are constrained; professionals should expect stable but not expanding roles focused on revenue defense.
Brand ManagerField Sales Representative
Worked on ZERIT XR at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.